Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy

Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy

Juno and Kite Pharma are under pressure Tuesday after U.S. government researchers published a study showing an off-the-shelf, engineered T-cell therapy could induce remissions in patients with blood cancers.

What to Watch When 3 Big Biotechs Report

What to Watch When 3 Big Biotechs Report

Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.

Juno Therapeutics Adds Next-Generation Single Cell Sequencing Capabilities Through Acquisition Of AbVitro

Juno Therapeutics Adds Next-Generation Single Cell Sequencing Capabilities Through Acquisition Of AbVitro

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired AbVitro, Inc.

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks

I'm only making one big prediction this year: The five-year party which saw biotech stocks outperform the broader markets comes to an end in 2016.

Juno Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference

Juno Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 34 th Annual J.

Editas' IPO Challenge: Edit Investor Expectations as Well as Diseased Genes

Editas' IPO Challenge: Edit Investor Expectations as Well as Diseased Genes

Editas Medicine is most definitely the hottest biotech initial public offering of a very young 2016.

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

My biotech and pharma superlatives for 2015.

Know When to Pull the Trigger

Know When to Pull the Trigger

Juno Therapeutics setup offers something for bulls and bears.

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

As the year winds down and the fund managers start selling stocks, Cramer will be watching for important earnings and economic data in a holiday-shortened week.

The Sky Is Falling, but It's Been Falling for a While

And I expect to see another rally this week.

'Mad Money' Lightning Round: Shopify Is Very Good, AT&T Is Steady

'Mad Money' Lightning Round: Shopify Is Very Good, AT&T Is Steady

Cramer sees Juno Therapeutics JUNO going lower and is taking MasterCard over First Data. FDC

Cancer Immunotherapy ETF Offers High Growth Investing Potential

Cancer Immunotherapy ETF Offers High Growth Investing Potential

Immunotherapy is changing the way the medical community thinks about treating cancer.

Cancer Immunotherapy ETF Offers High Growth Investing Option

Cancer Immunotherapy ETF Offers High Growth Investing Option

Immunotherapy is changing the way the medical community thinks about treating cancer.

'Mad Money' Lightning Round: Take a Longer View on Skechers

'Mad Money' Lightning Round: Take a Longer View on Skechers

Cramer prefers Biogen Idec over Juno Therapeutics and is avoiding Potash.

Jim Cramer's 'Mad Money' Recap: Don't Leave the Market's Table Now

Jim Cramer's 'Mad Money' Recap: Don't Leave the Market's Table Now

Worried about an interest rate hike? Selling now along with everyone else won't prove to be a smart strategy, Cramer says.

Juno's Investigational CAR T Cell Product Candidates JCAR015 And JCAR014 Demonstrate Encouraging Clinical Responses In Patients With B-cell Cancers

Juno's Investigational CAR T Cell Product Candidates JCAR015 And JCAR014 Demonstrate Encouraging Clinical Responses In Patients With B-cell Cancers

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, that...

Juno's Investigational CAR T Cell Product Candidates JCAR014 And JCAR018 Demonstrate Encouraging Clinical Responses In Patients With B-Cell Cancers

Juno's Investigational CAR T Cell Product Candidates JCAR014 And JCAR018 Demonstrate Encouraging Clinical Responses In Patients With B-Cell Cancers

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, that...

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

That's especially true during December when the analysts often have nice things to say to help boost their funds going into the end of the year, Cramer says.

Juno Therapeutics Announces Data Presentations At The American Society Of Hematology Annual Meeting

Juno Therapeutics Announces Data Presentations At The American Society Of Hematology Annual Meeting

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced the Company, in partnership with its...

Juno Therapeutics (JUNO) Stock is the ‘Chart of the Day’

Juno Therapeutics (JUNO) Stock is the ‘Chart of the Day’

Juno Therapeutics (JUNO) stock is Monday’s ‘Chart of the Day.’

Juno Could Jump 10%

Juno Could Jump 10%

It's a volatile name showing good relative strength.

Chart of the Day: Juno

Juno gets its sea legs.

Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy

Goldman Sees Bluebird Shares Doubling On 'One-Shot' Gene Therapy

Following a three and a half year rally for biotech stocks Goldman Sachs analyst said that he has a Neutral view of the small- to mid-cap biotech space.

'Mad Money' Lightning Round: Procter & Gamble Is Done Going Down

'Mad Money' Lightning Round: Procter & Gamble Is Done Going Down

Cramers says to buy Skechers and take Eli Lilly over Pfizer.

Jim Cramer's 'Mad Money' Recap: Why Good News Is Bad News in This Market

Jim Cramer's 'Mad Money' Recap: Why Good News Is Bad News in This Market

It's too darn hard to make a profit nowadays, Cramer says.

Juno Stock Falls in After-Hours Trading on Earnings Results

Juno Stock Falls in After-Hours Trading on Earnings Results

Juno stock is down in after-hours trading, following the release of the company's 2015 third quarter financial results after the market close today.

Juno Therapeutics Reports Third Quarter 2015 Financial Results

Juno Therapeutics Reports Third Quarter 2015 Financial Results

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the...

What to Watch Tuesday: Will D.R. Horton Build Investor Confidence?

What to Watch Tuesday: Will D.R. Horton Build Investor Confidence?

Other companies reporting earnings on Tuesday include Vodefone Group and Tribune Media.

What to Watch Tuesday: Will D.R. Horton Build Investor Confidence?

What to Watch Tuesday: Will D.R. Horton Build Investor Confidence?

For Tuesday November 10, TheStreet highlights the remainder of the companies reporting financial results as the earnings season trails off.

Juno Therapeutics To Present At The Credit Suisse 24th Annual Healthcare Conference

Juno Therapeutics To Present At The Credit Suisse 24th Annual Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Credit Suisse 24 th Annual Healthcare Conference at 10:00 a.